Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
More studies link dolutegravir and other drugs to weight gain among people with HIV.
Only one company will sell a version of the HIV prevention pill Truvada. When others go to market, prices will likely drop further.
The Food and Drug Administration recently approved a generic formulation of Gilead Sciences’ antiretroviral Truvada.
Although more research on antiretroviral linked bone loss is needed, the overall health benefits of early treatment outweigh such a risk.
New trial compares Descovy to Truvada.
The trial will test a regimen of Tivicay (dolutegravir) plus Epivir (lamivudine) against Tivicay and Truvada (tenofovir/emtricitabine).
Gilead Sciences has filed for approval of Truvada as pre-exposure prophylaxis (PrEP) against HIV with the European Medicines Agency.
Two documented cases of men taking Viread (tenofovir), one of two drugs in Truvada (tenofovir/emtricitabine), for hep B and contracting HIV.
Truvada as pre-exposure prophylaxis (PrEP), unapproved in the United Kingdom, could dramatically reduce new infections among gay men there.
Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.
Truvada as pre-exposure prophylaxis (PrEP) against HIV has comparable safety to aspirin, at least for the short- and medium-term.
Following years of apparent stagnation in the U.S. fight against HIV, reports now suggest that things are looking up. What’s the full story?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.